KR101205257B1 - 피부 상태 또는 암 치료를 위한 ｓｃｃｅ 저해제로서의 융합된 헤테로사이클 화합물의 용도 - Google Patents

피부 상태 또는 암 치료를 위한 ｓｃｃｅ 저해제로서의 융합된 헤테로사이클 화합물의 용도 Download PDF

Info

Publication number
KR101205257B1
KR101205257B1 KR1020117022051A KR20117022051A KR101205257B1 KR 101205257 B1 KR101205257 B1 KR 101205257B1 KR 1020117022051 A KR1020117022051 A KR 1020117022051A KR 20117022051 A KR20117022051 A KR 20117022051A KR 101205257 B1 KR101205257 B1 KR 101205257B1
Authority
KR
South Korea
Prior art keywords
phenyl
oxazin
benzo
thieno
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117022051A
Other languages
English (en)
Korean (ko)
Other versions
KR20110120960A (ko
Inventor
마르셀 린쇼텐
Original Assignee
아렉시스 악티에볼라그
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아렉시스 악티에볼라그 filed Critical 아렉시스 악티에볼라그
Publication of KR20110120960A publication Critical patent/KR20110120960A/ko
Application granted granted Critical
Publication of KR101205257B1 publication Critical patent/KR101205257B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020117022051A 2003-06-06 2004-06-07 피부 상태 또는 암 치료를 위한 ｓｃｃｅ 저해제로서의 융합된 헤테로사이클 화합물의 용도 Expired - Fee Related KR101205257B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA200300840 2003-06-06
DKPA200300844 2003-06-06
DKPA200300844 2003-06-06
DKPA200300842 2003-06-06
DKPA200300842 2003-06-06
DKPA200300840 2003-06-06
DKPA200300843 2003-06-06
DKPA200300843 2003-06-06
PCT/DK2004/000388 WO2004108139A2 (en) 2003-06-06 2004-06-07 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020057023349A Division KR101099409B1 (ko) 2003-06-06 2004-06-07 피부 상태 또는 암 치료를 위한 ｓｃｃｅ 저해제로서의융합된 헤테로사이클 화합물의 용도

Publications (2)

Publication Number Publication Date
KR20110120960A KR20110120960A (ko) 2011-11-04
KR101205257B1 true KR101205257B1 (ko) 2012-11-27

Family

ID=33514772

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117022051A Expired - Fee Related KR101205257B1 (ko) 2003-06-06 2004-06-07 피부 상태 또는 암 치료를 위한 ｓｃｃｅ 저해제로서의 융합된 헤테로사이클 화합물의 용도
KR1020057023349A Expired - Fee Related KR101099409B1 (ko) 2003-06-06 2004-06-07 피부 상태 또는 암 치료를 위한 ｓｃｃｅ 저해제로서의융합된 헤테로사이클 화합물의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020057023349A Expired - Fee Related KR101099409B1 (ko) 2003-06-06 2004-06-07 피부 상태 또는 암 치료를 위한 ｓｃｃｅ 저해제로서의융합된 헤테로사이클 화합물의 용도

Country Status (17)

Country Link
US (1) US7872052B2 (https=)
EP (1) EP1631295B1 (https=)
JP (1) JP5044214B2 (https=)
KR (2) KR101205257B1 (https=)
CN (1) CN101152185B (https=)
AT (1) ATE459359T1 (https=)
CA (1) CA2525383C (https=)
CY (1) CY1110084T1 (https=)
DE (1) DE602004025803D1 (https=)
DK (1) DK1631295T3 (https=)
ES (1) ES2341545T3 (https=)
NO (1) NO20060091L (https=)
NZ (1) NZ543636A (https=)
PL (1) PL1631295T3 (https=)
PT (1) PT1631295E (https=)
SI (1) SI1631295T1 (https=)
WO (1) WO2004108139A2 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
CA2617213C (en) * 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PL2066662T3 (pl) 2006-09-21 2013-05-31 Kyorin Seiyaku Kk Inhibitory hydrolaz serynowych
WO2008041118A2 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
WO2009024528A1 (en) 2007-08-17 2009-02-26 Novartis Ag Use of cyclic depsipeptides to inhibit kallikrein 7
MY151973A (en) 2007-08-17 2014-07-31 Novartis Ag Cyclic depsipeptides
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja) 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
EP2403857B1 (en) * 2009-03-05 2013-12-04 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
NZ755378A (en) 2009-03-18 2022-07-29 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
PE20120505A1 (es) 2009-03-31 2012-05-09 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
KR20190091564A (ko) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 신규한 소염제
TWI419884B (zh) * 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物
AP2012006631A0 (en) 2010-08-12 2012-12-31 Boehringer Ingelheim Int 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US8614289B2 (en) 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
RU2640115C2 (ru) 2011-11-01 2017-12-26 Ресверлоджикс Корп. Фармацевтические композиции замещенных хиназолинонов
KR20140138293A (ko) 2012-03-16 2014-12-03 액시킨 파마수티컬스 인코포레이티드 3,5-다이아미노피라졸 키나아제 억제제
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
PT3097084T (pt) 2014-01-23 2020-12-09 Sixera Pharma Ab Novos inibidores de calicreína 7
DK3097085T3 (da) 2014-01-23 2020-10-26 Sixera Pharma Ab Benzoxazinonderivater til behandling af hudsygdomme
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN108421034A (zh) * 2018-04-24 2018-08-21 济南磐升生物技术有限公司 激肽释放酶7在皮肤创伤愈合中的应用
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
TWI803696B (zh) 2018-09-14 2023-06-01 日商橘生藥品工業股份有限公司 次黃嘌呤化合物
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN113939296A (zh) 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11643420B2 (en) 2019-10-01 2023-05-09 Molecular Skin Therapeutics, Inc. Benzoxazinone compounds as KLK5/7 dual inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7502945B2 (ja) * 2020-09-08 2024-06-19 花王株式会社 デリケートエリアのかぶれの検査方法
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024520154A (ja) 2021-06-01 2024-05-21 シクセラ・ファーマ・アーベー ６－エトキシ－７－メトキシ－２－（２－メチルスルファニルフェニル）－３，１－ベンゾオキサジン－４－オンの水中油型乳剤
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US20250388573A1 (en) * 2022-06-21 2025-12-25 Dana-Farber Cancer Institute, Inc. Fused bicyclic egfr inhibitors and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006921A1 (en) 1988-12-21 1990-06-28 The Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
FR2121341A1 (en) * 1971-01-04 1972-08-25 Ferlux 2-substd-3,1-benzoxazin-4-ones - antiinflammatories, analgesics sedatives and diuretics
IT1050750B (it) * 1975-12-05 1981-03-20 Erba Carlo Spa Derivati della 3.4 di idro chinazolina
JPS5576868A (en) 1978-12-01 1980-06-10 Hisamitsu Pharmaceut Co Inc Novel 3,1-bezoxazine derivative
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
JPH07316056A (ja) * 1990-02-15 1995-12-05 Teijin Ltd エラスターゼ阻害用医薬組成物
AU635403B2 (en) * 1990-02-15 1993-03-18 Teijin Limited 4h-3,1-benzoxazin-4-one compound and elastase inhibitor composition containing the same
JPH05509302A (ja) * 1990-06-20 1993-12-22 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5346886A (en) * 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
AU1375000A (en) * 1998-11-26 2000-06-13 Novo Nordisk A/S Heterocyclic compounds regulating clotting
EP1212097B1 (en) * 1999-09-10 2005-11-16 The Procter & Gamble Company Enzyme inhibitors
ATE515940T1 (de) 2001-02-09 2011-07-15 Torbjoern Egelrud Scce transgene mäuse und deren verwendung als modell für menschliche krankheiten
WO2003007955A2 (en) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
CA2503674A1 (en) * 2002-10-03 2004-04-15 Institute Of Medicinal Molecular Design, Inc. Quinazolin-4-one derivatives
CA2502302A1 (en) * 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006921A1 (en) 1988-12-21 1990-06-28 The Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Also Published As

Publication number Publication date
WO2004108139A2 (en) 2004-12-16
WO2004108139A8 (en) 2005-04-28
HK1091731A1 (zh) 2007-01-26
WO2004108139A3 (en) 2005-03-10
DK1631295T3 (da) 2010-06-21
CN101152185A (zh) 2008-04-02
CY1110084T1 (el) 2015-01-14
ES2341545T3 (es) 2010-06-22
JP2006526581A (ja) 2006-11-24
AU2004244704A1 (en) 2004-12-16
CA2525383A1 (en) 2004-12-16
CA2525383C (en) 2012-03-06
KR20110120960A (ko) 2011-11-04
CN101152185B (zh) 2010-12-08
EP1631295B1 (en) 2010-03-03
KR101099409B1 (ko) 2011-12-27
SI1631295T1 (sl) 2010-06-30
EP1631295A2 (en) 2006-03-08
JP5044214B2 (ja) 2012-10-10
PL1631295T3 (pl) 2010-09-30
NZ543636A (en) 2009-07-31
ATE459359T1 (de) 2010-03-15
KR20060008331A (ko) 2006-01-26
US20060258651A1 (en) 2006-11-16
PT1631295E (pt) 2010-05-24
DE602004025803D1 (de) 2010-04-15
NO20060091L (no) 2006-03-06
US7872052B2 (en) 2011-01-18
HK1120209A1 (en) 2009-03-27

Similar Documents

Publication Publication Date Title
KR101205257B1 (ko) 피부 상태 또는 암 치료를 위한 ｓｃｃｅ 저해제로서의 융합된 헤테로사이클 화합물의 용도
EP2547676B1 (en) Modulators of hec1 activity and methods therefor
JP2010520293A (ja) 複素環式部分を含有するメタロプロテアーゼ阻害剤
JP2003526594A (ja) カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法
CA2521152A1 (en) Use of a topical medicament comprising riluzole
EP3049389B1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TW201305167A (zh) 使用經鹵芳基取代之胺基嘌呤的治療、改善及預防方法
WO2024078592A1 (zh) 靶向成纤维细胞活化蛋白的药物及其应用
KR20220091488A (ko) Klk5/7 이중 억제제로서의 벤족사지논 화합물
CA2782472A1 (en) Method of treating scars and beta-catenin-mediated disorders
TW202219056A (zh) 巨環化合物及其使用方法
CN100518740C (zh) 杂环化合物作为scce抑制剂的制药用途
AU2004244704B2 (en) Use of fused heterocyclic compounds as SCCE inhibitors for the treatment of skin conditions or cancer
JP2010529096A (ja) チロシナーゼ阻害剤として使用される新規の４−フェニルイミダゾール−２−チオン、その調製方法ならびにヒトの医学および化粧品学におけるその使用
HK1091731B (en) Pharmaceutical use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
HK1120209B (en) Use of fused heterocyclic compounds as scce inhibitors
JP2003502362A (ja) 化学療法および／または放射線療法の副作用の苛酷さを防止／軽減するための組成物および方法
WO2000030646A1 (en) Heterocyclic compounds regulating clotting
JP2003501389A (ja) トロンビン阻害物質
JPH08500120A (ja) 置換アザスピランを用いる乾癬の治療方法
US20160144006A1 (en) Maspin, Maspin Derivatives, and Maspin Mimetics for Reducing ROS, Inflammation, and Skin Aging
US20130203789A1 (en) Novel Inhibitors of LYN Kinase and Methods Using Same
US20130203817A1 (en) Novel Inhibitors of LYN Kinase
WO2024114765A9 (zh) 苯并吡喃酮类化合物、其制备方法及其应用
CN119638779A (zh) 一种乏氧响应性蛋白降解靶向嵌合体化合物及其制备方法和应用

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20151102

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20171122

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20171122

St.27 status event code: N-4-6-H10-H13-oth-PC1903